Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul;3(7):e470-e472.
doi: 10.1016/S2665-9913(21)00186-7. Epub 2021 Jun 8.

Anti-SARS-CoV-2 mRNA vaccine in patients with rheumatoid arthritis

Andrea Rubbert-Roth  1 , Nicolas Vuilleumier  2 , Burkhard Ludewig  3   4 , Kristin Schmiedeberg  1 , Christoph Haller  1 , Johannes von Kempis  1
Affiliations

Anti-SARS-CoV-2 mRNA vaccine in patients with rheumatoid arthritis

Andrea Rubbert-Roth et al. Lancet Rheumatol. 2021 Jul.
No abstract available

PubMed Disclaimer

Conflict of interest statement

AR-R reports consulting fees from AbbVie, Gilead, Lilly, BMS, and Sanofi, honoraria from AbbVie, Pfizer, Sanofi, UCB, BMS, Lilly, Gilead, and Roche, payment for expert testimony from AbbVie and Gilead, support for travel or meeting attendance from Sanofi, Roche, and AbbVie, and compensation for participation on a Data Safety Monitoring Board from R-Pharm. KS reports support for travel or meeting attendance from AbbVie Deutschland. JvK reports consulting fees from AbbVie, BMS, Pfizer, and Sanofi, honoraria from Eli Lilly, and support for travel or meeting attendance from Pfizer. All other authors declare no competing interests. All authors have access to all the data in the study. AR-R and JvK accessed and verified all the data in the study. The RECOVER trial is registered by the Business Administration System for Ethics Committees (number2021-00156).

Figures

Figure
Figure
Anti-SARS-CoV-2 S1 serum antibodies from patients with rheumatoid arthritis Patients with rheumatoid arthritis (n=51) and healthy control individuals (n=20) before vaccination and at the indicated time points following their first and second vaccination. Symbols show individual values, horizontal bars show medians, horizontal dotted lines show lower (0·4 U/mL) and upper (2500 U/mL) detection limits. Double red triangles show control individuals. Single red triangles show patients with rheumatoid arthritis. Blue triangles show patients with rheumatoid arthritis who were receiving Janus kinase inhibitors. Statistical analysis was done using the Mann–Whitney test for non-parametric data.
See this image and copyright information in PMC

References

    1. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. 2020;383:2603–2615. - PMC - PubMed
    1. Walsh EE, Frenck RW, Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based COVID-19 vaccine candidates. N Engl J Med. 2020;383:2439–2450. - PMC - PubMed
    1. Boyarsky BJ, Ruddy JA, Connolly CM, et al. Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases. Ann Rheum Dis. 2021 doi: 10.1136/annrheumdis-2021-220289. published online March 23. - DOI - PMC - PubMed
    1. Geisen UM, Berner DK, Tran F, et al. Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort. Ann Rheum Dis. 2021 doi: 10.1136/annrheumdis-2021-220272. published online March 24. - DOI - PMC - PubMed
    1. Sadoff J, Gray G, Vandebosch A, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against COVID-19. N Engl J Med. 2021 doi: 10.1056/NEJMoa2101544. published online April 21. - DOI - PMC - PubMed

LinkOut - more resources